Table 3.
Disease characteristics of recently diagnosed and established MDS patients*
| Recently diagnosed patients, % (95% CI) (N = 670) | Established patients, % per survey (N = 4514) |
||||||
| Characteristic | Survey 1 (n = 614) | Survey 2 (n = 664) | Survey 3 (n = 816) | Survey 4 (n = 789) | Survey 5 (n = 804) | Survey 6 (n = 827) | |
| FAB classification | |||||||
| RA | 38 (34 to 41) | 45 | 44 | 46 | 44 | 49 | 52 |
| RARS | 12 (9 to 14) | 16 | 19 | 14 | 18 | 16 | 17 |
| RAEB | 16 (14 to 19) | 16 | 13 | 14 | 12 | 14 | 12 |
| RAEBt | 10 (7 to 12) | 6 | 5 | 4 | 3 | 3 | 4 |
| CMML | 5 (4 to 7) | 7 | 6 | 3 | 4 | 4 | 4 |
| Unclassifiable | 5 (3 to 7) | 7 | 8 | 6 | 6 | 5 | 3 |
| Missing FAB | 14 (12 to 17) | 4 | 5 | 14 | 12 | 8 | 10 |
| WHO classification | |||||||
| RARS | 13 (10 to 15) | 13 | 13 | 14 | 15 | 13 | 14 |
| RCMD | 20 (17 to 23) | 24 | 21 | 24 | 19 | 22 | 21 |
| RCMD-RS | 1 (0 to 2) | 2 | 2 | 3 | 2 | 3 | 3 |
| RAEB-1 | 11 (8 to 13) | 11 | 8 | 9 | 8 | 9 | 9 |
| RAEB-2 | 12 (10 to 15) | 10 | 7 | 5 | 6 | 4 | 3 |
| MDS-U | 13 (11 to 16) | 4 | 3 | 3 | 3 | 4 | 4 |
| MDS, isolated del(5q) | 4 (2 to 5) | 23 | 19 | 16 | 19 | 15 | 17 |
| Missing WHO | 27 (23 to 30) | 13 | 28 | 25 | 28 | 30 | 29 |
| IPSS risk score | |||||||
| Low | 30 (27 to 33) | 37 | 40 | 38 | 44 | 41 | 40 |
| Intermediate-1 | 34 (31 to 38) | 38 | 38 | 39 | 34 | 38 | 39 |
| Intermediate-2 | 16 (13 to 19) | 12 | 13 | 13 | 8 | 12 | 15 |
| High | 13 (11 to 16) | 13 | 5 | 5 | 7 | 7 | 5 |
| Missing IPSS | 6 (4 to 8) | 0 | 4 | 5 | 7 | 3 | 2 |
The total “n” listed at the heading of each established patients survey column includes recently diagnosed (ie, diagnosed in the previous 2 months) and established patients for whom this information was collected in that survey. Results for recently diagnosed patients were combined from across all six surveys and reported along with 95% CIs. MDS = myelodysplastic syndrome; CI = confidence interval; FAB = French–American–British; RA = refractory anemia; RARS = refractory anemia with ringed sideroblasts; RAEB = refractory anemia with excess of blasts; RAEBt = refractory anemia with excess of blasts in transformation; CMML = chronic myelomonocytic leukemia; WHO = World Health Organization; RCMD = refractory cytopenia with multilineage dysplasia; RCMD-RS = refractory cytopenia with multilineage dysplasia with ringed sideroblasts; MDS-U = myelodysplastic syndrome unclassified; IPSS = International Prognostic Scoring System.